The PCIP program is a critically important component of the ACA market reforms because it affords those patients that currently lack insurance coverage due to these discriminatory practices an opportunity to enjoy temporary coverage until they can transition to meaningful coverage on January 1, 2014. To sign onto the letter please contact Jen Bernstein at firstname.lastname@example.org buy April 15th 1pm Eastern.
The decision in February to suspend PCIP enrollment could have catastrophic consequences for the rare disease patient community because of treatment delays. Impediments to accessing rare disease therapies not only lead to poor health outcomes, but also drive up health care costs due to increased physician office visits, emergency room interventions, hospital admissions, surgical interventions.
Read the full letter: Patient Sign on Letter PCIP Program FINAL REVISED DRAFT